ADAMTS13

Across TCGA pan-cancer cohorts, ADAMTS13 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADAMTS13 data layer compared with 22 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAMTS13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADAMTS13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where ADAMTS13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.939	0.401	.017	15	view →
LSCC	OS	Median	II,III,IV	0.689	1.000	.033	2	view →
HNSC	OS	Median	II,III,IV	0.902	0.519	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADAMTS13–PDAC (OS)

Open the PDAC breakdown →